Methods and compositions for treating cancer
US9650428B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2015 |
| Grant date | May 16, 2017 |
| Priority date | — |
| Expiry date | Dec 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/13043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are compositions and methods relating to immune cells which express both a chimeric antigen receptor which binds to the IL13 receptor α-2 (IL13Rα2) and a O6-methylguanine DNA methyltransferase (MGMT) protein. Viral particles containing an IL13 chimeric antigen receptor (IL13CAR) or variant thereof and an MGMT protein or variant thereof are used to transfect immune cells such as T cells, imparting to the transfected cells both IL13Rα2-targeting activity and resistance to the chemotherapeutic agent temozolomide (TMZ). The compositions and methods described are useful for cancer therapy such as the treatment of a high-grade malignant glioma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.